Global Metabolic Disorder Therapeutics Market Research Report 2024

Metabolic Disorder Therapeutics Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Metabolic Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disorder Therapeutics.

Report Scope

The Metabolic Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metabolic Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Metabolic Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Novo Nordisk A/S

Sanofi S.A.

Boehringer Ingelheim GmbH

Eli Lilly and Company

Merck KgaA

Amgen, Inc.

AstraZeneca PLC

Actelion Pharmaceuticals Ltd.

Shire PLC

AbbVie, Inc.

Biocon Ltd.

BioMarin Pharmaceutical, Inc.

Bristol-Myers Squibb Company

Cipla, Inc.

CymaBay Therapeutics, Inc.

Lysosomal Storage Diseases

Diabetes

Obesity

Inherited Metabolic Disorders

Hypercholesterolemia

Oral

Parenteral

Others

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Scope of Metabolic Disorder Therapeutics Market Report

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Metabolic Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Lysosomal Storage Diseases

1.2.3 Diabetes

1.2.4 Obesity

1.2.5 Inherited Metabolic Disorders

1.2.6 Hypercholesterolemia

1.3 Market by Application

1.3.1 Global Metabolic Disorder Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Oral

1.3.3 Parenteral

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Metabolic Disorder Therapeutics Market Perspective (2019-2030)

2.2 Metabolic Disorder Therapeutics Growth Trends by Region

2.2.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Metabolic Disorder Therapeutics Market Dynamics

2.3.1 Metabolic Disorder Therapeutics Industry Trends

2.3.2 Metabolic Disorder Therapeutics Market Drivers

2.3.3 Metabolic Disorder Therapeutics Market Challenges

2.3.4 Metabolic Disorder Therapeutics Market Restraints

3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue

3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue

3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio

3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2023

3.5 Metabolic Disorder Therapeutics Key Players Head office and Area Served

3.6 Key Players Metabolic Disorder Therapeutics Product Solution and Service

3.7 Date of Enter into Metabolic Disorder Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2025-2030)

5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2025-2030)

6.1 North America Metabolic Disorder Therapeutics Market Size (2019-2030)

6.2 North America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Metabolic Disorder Therapeutics Market Size by Country (2019-2024)

6.4 North America Metabolic Disorder Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7.1 Europe Metabolic Disorder Therapeutics Market Size (2019-2030)

7.2 Europe Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Metabolic Disorder Therapeutics Market Size by Country (2019-2024)

7.4 Europe Metabolic Disorder Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Metabolic Disorder Therapeutics Market Size (2019-2030)

9.2 Latin America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Metabolic Disorder Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Novo Nordisk A/S

11.1.1 Novo Nordisk A/S Company Detail

11.1.2 Novo Nordisk A/S Business Overview

11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction

11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.1.5 Novo Nordisk A/S Recent Development

11.2 Sanofi S.A.

11.2.1 Sanofi S.A. Company Detail

11.2.2 Sanofi S.A. Business Overview

11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction

11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.2.5 Sanofi S.A. Recent Development

11.3 Boehringer Ingelheim GmbH

11.3.1 Boehringer Ingelheim GmbH Company Detail

11.3.2 Boehringer Ingelheim GmbH Business Overview

11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction

11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.3.5 Boehringer Ingelheim GmbH Recent Development

11.4 Eli Lilly and Company

11.4.1 Eli Lilly and Company Company Detail

11.4.2 Eli Lilly and Company Business Overview

11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction

11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.4.5 Eli Lilly and Company Recent Development

11.5 Merck KgaA

11.5.1 Merck KgaA Company Detail

11.5.2 Merck KgaA Business Overview

11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction

11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.5.5 Merck KgaA Recent Development

11.6 Amgen, Inc.

11.6.1 Amgen, Inc. Company Detail

11.6.2 Amgen, Inc. Business Overview

11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction

11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.6.5 Amgen, Inc. Recent Development

11.7 AstraZeneca PLC

11.7.1 AstraZeneca PLC Company Detail

11.7.2 AstraZeneca PLC Business Overview

11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction

11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.7.5 AstraZeneca PLC Recent Development

11.8 Actelion Pharmaceuticals Ltd.

11.8.1 Actelion Pharmaceuticals Ltd. Company Detail

11.8.2 Actelion Pharmaceuticals Ltd. Business Overview

11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction

11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.8.5 Actelion Pharmaceuticals Ltd. Recent Development

11.9 Shire PLC

11.9.1 Shire PLC Company Detail

11.9.2 Shire PLC Business Overview

11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction

11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.9.5 Shire PLC Recent Development

11.10 AbbVie, Inc.

11.10.1 AbbVie, Inc. Company Detail

11.10.2 AbbVie, Inc. Business Overview

11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction

11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.10.5 AbbVie, Inc. Recent Development

11.11 Biocon Ltd.

11.11.1 Biocon Ltd. Company Detail

11.11.2 Biocon Ltd. Business Overview

11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction

11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.11.5 Biocon Ltd. Recent Development

11.12 BioMarin Pharmaceutical, Inc.

11.12.1 BioMarin Pharmaceutical, Inc. Company Detail

11.12.2 BioMarin Pharmaceutical, Inc. Business Overview

11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction

11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.12.5 BioMarin Pharmaceutical, Inc. Recent Development

11.13 Bristol-Myers Squibb Company

11.13.1 Bristol-Myers Squibb Company Company Detail

11.13.2 Bristol-Myers Squibb Company Business Overview

11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction

11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.13.5 Bristol-Myers Squibb Company Recent Development

11.14 Cipla, Inc.

11.14.1 Cipla, Inc. Company Detail

11.14.2 Cipla, Inc. Business Overview

11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction

11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.14.5 Cipla, Inc. Recent Development

11.15 CymaBay Therapeutics, Inc.

11.15.1 CymaBay Therapeutics, Inc. Company Detail

11.15.2 CymaBay Therapeutics, Inc. Business Overview

11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction

11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.15.5 CymaBay Therapeutics, Inc. Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

    Table 2. Key Players of Lysosomal Storage Diseases

    Table 3. Key Players of Diabetes

    Table 4. Key Players of Obesity

    Table 5. Key Players of Inherited Metabolic Disorders

    Table 6. Key Players of Hypercholesterolemia

    Table 7. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

    Table 8. Global Metabolic Disorder Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

    Table 9. Global Metabolic Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)

    Table 10. Global Metabolic Disorder Therapeutics Market Share by Region (2019-2024)

    Table 11. Global Metabolic Disorder Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

    Table 12. Global Metabolic Disorder Therapeutics Market Share by Region (2025-2030)

    Table 13. Metabolic Disorder Therapeutics Market Trends

    Table 14. Metabolic Disorder Therapeutics Market Drivers

    Table 15. Metabolic Disorder Therapeutics Market Challenges

    Table 16. Metabolic Disorder Therapeutics Market Restraints

    Table 17. Global Metabolic Disorder Therapeutics Revenue by Players (2019-2024) & (US$ Million)

    Table 18. Global Metabolic Disorder Therapeutics Market Share by Players (2019-2024)

    Table 19. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2023)

    Table 20. Ranking of Global Top Metabolic Disorder Therapeutics Companies by Revenue (US$ Million) in 2023

    Table 21. Global 5 Largest Players Market Share by Metabolic Disorder Therapeutics Revenue (CR5 and HHI) & (2019-2024)

    Table 22. Key Players Headquarters and Area Served

    Table 23. Key Players Metabolic Disorder Therapeutics Product Solution and Service

    Table 24. Date of Enter into Metabolic Disorder Therapeutics Market

    Table 25. Mergers & Acquisitions, Expansion Plans

    Table 26. Global Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)

    Table 27. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2019-2024)

    Table 28. Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

    Table 29. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2025-2030)

    Table 30. Global Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)

    Table 31. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2019-2024)

    Table 32. Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

    Table 33. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2025-2030)

    Table 34. North America Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 35. North America Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)

    Table 36. North America Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)

    Table 37. Europe Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 38. Europe Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)

    Table 39. Europe Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)

    Table 40. Asia-Pacific Metabolic Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

    Table 41. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)

    Table 42. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2025-2030) & (US$ Million)

    Table 43. Latin America Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 44. Latin America Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)

    Table 45. Latin America Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)

    Table 46. Middle East & Africa Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 47. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)

    Table 48. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)

    Table 49. Novo Nordisk A/S Company Detail

    Table 50. Novo Nordisk A/S Business Overview

    Table 51. Novo Nordisk A/S Metabolic Disorder Therapeutics Product

    Table 52. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 53. Novo Nordisk A/S Recent Development

    Table 54. Sanofi S.A. Company Detail

    Table 55. Sanofi S.A. Business Overview

    Table 56. Sanofi S.A. Metabolic Disorder Therapeutics Product

    Table 57. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 58. Sanofi S.A. Recent Development

    Table 59. Boehringer Ingelheim GmbH Company Detail

    Table 60. Boehringer Ingelheim GmbH Business Overview

    Table 61. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product

    Table 62. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 63. Boehringer Ingelheim GmbH Recent Development

    Table 64. Eli Lilly and Company Company Detail

    Table 65. Eli Lilly and Company Business Overview

    Table 66. Eli Lilly and Company Metabolic Disorder Therapeutics Product

    Table 67. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 68. Eli Lilly and Company Recent Development

    Table 69. Merck KgaA Company Detail

    Table 70. Merck KgaA Business Overview

    Table 71. Merck KgaA Metabolic Disorder Therapeutics Product

    Table 72. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 73. Merck KgaA Recent Development

    Table 74. Amgen, Inc. Company Detail

    Table 75. Amgen, Inc. Business Overview

    Table 76. Amgen, Inc. Metabolic Disorder Therapeutics Product

    Table 77. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 78. Amgen, Inc. Recent Development

    Table 79. AstraZeneca PLC Company Detail

    Table 80. AstraZeneca PLC Business Overview

    Table 81. AstraZeneca PLC Metabolic Disorder Therapeutics Product

    Table 82. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 83. AstraZeneca PLC Recent Development

    Table 84. Actelion Pharmaceuticals Ltd. Company Detail

    Table 85. Actelion Pharmaceuticals Ltd. Business Overview

    Table 86. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product

    Table 87. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 88. Actelion Pharmaceuticals Ltd. Recent Development

    Table 89. Shire PLC Company Detail

    Table 90. Shire PLC Business Overview

    Table 91. Shire PLC Metabolic Disorder Therapeutics Product

    Table 92. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 93. Shire PLC Recent Development

    Table 94. AbbVie, Inc. Company Detail

    Table 95. AbbVie, Inc. Business Overview

    Table 96. AbbVie, Inc. Metabolic Disorder Therapeutics Product

    Table 97. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 98. AbbVie, Inc. Recent Development

    Table 99. Biocon Ltd. Company Detail

    Table 100. Biocon Ltd. Business Overview

    Table 101. Biocon Ltd. Metabolic Disorder Therapeutics Product

    Table 102. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 103. Biocon Ltd. Recent Development

    Table 104. BioMarin Pharmaceutical, Inc. Company Detail

    Table 105. BioMarin Pharmaceutical, Inc. Business Overview

    Table 106. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product

    Table 107. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 108. BioMarin Pharmaceutical, Inc. Recent Development

    Table 109. Bristol-Myers Squibb Company Company Detail

    Table 110. Bristol-Myers Squibb Company Business Overview

    Table 111. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product

    Table 112. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 113. Bristol-Myers Squibb Company Recent Development

    Table 114. Cipla, Inc. Company Detail

    Table 115. Cipla, Inc. Business Overview

    Table 116. Cipla, Inc. Metabolic Disorder Therapeutics Product

    Table 117. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 118. Cipla, Inc. Recent Development

    Table 119. CymaBay Therapeutics, Inc. Company Detail

    Table 120. CymaBay Therapeutics, Inc. Business Overview

    Table 121. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product

    Table 122. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

    Table 123. CymaBay Therapeutics, Inc. Recent Development

    Table 124. Research Programs/Design for This Report

    Table 125. Key Data Information from Secondary Sources

    Table 126. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Metabolic Disorder Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

    Figure 2. Global Metabolic Disorder Therapeutics Market Share by Type: 2023 VS 2030

    Figure 3. Lysosomal Storage Diseases Features

    Figure 4. Diabetes Features

    Figure 5. Obesity Features

    Figure 6. Inherited Metabolic Disorders Features

    Figure 7. Hypercholesterolemia Features

    Figure 8. Global Metabolic Disorder Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

    Figure 9. Global Metabolic Disorder Therapeutics Market Share by Application: 2023 VS 2030

    Figure 10. Oral Case Studies

    Figure 11. Parenteral Case Studies

    Figure 12. Others Case Studies

    Figure 13. Metabolic Disorder Therapeutics Report Years Considered

    Figure 14. Global Metabolic Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

    Figure 15. Global Metabolic Disorder Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

    Figure 16. Global Metabolic Disorder Therapeutics Market Share by Region: 2023 VS 2030

    Figure 17. Global Metabolic Disorder Therapeutics Market Share by Players in 2023

    Figure 18. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2023)

    Figure 19. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2023

    Figure 20. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 21. North America Metabolic Disorder Therapeutics Market Share by Country (2019-2030)

    Figure 22. United States Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 23. Canada Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 24. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 25. Europe Metabolic Disorder Therapeutics Market Share by Country (2019-2030)

    Figure 26. Germany Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 27. France Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 28. U.K. Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 29. Italy Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 30. Russia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 31. Nordic Countries Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 32. Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 33. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Region (2019-2030)

    Figure 34. China Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 35. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 36. South Korea Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 37. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 38. India Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 39. Australia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 40. Latin America Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 41. Latin America Metabolic Disorder Therapeutics Market Share by Country (2019-2030)

    Figure 42. Mexico Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 43. Brazil Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 44. Middle East & Africa Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 45. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Country (2019-2030)

    Figure 46. Turkey Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 47. Saudi Arabia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 48. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 49. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 50. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 51. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 52. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 53. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 54. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 55. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 56. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 57. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 58. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 59. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 61. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 62. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

    Figure 63. Bottom-up and Top-down Approaches for This Report

    Figure 64. Data Triangulation

    Figure 65. Key Executives Interviewed